Literature DB >> 23307061

Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.

Elizabeth L Courville1, Yue Wu, Jihen Kourda, Christine G Roth, Jillian Brockmann, Alona Muzikansky, Amir T Fathi, Laurence de Leval, Attilio Orazi, Robert P Hasserjian.   

Abstract

Acute myeloid leukemia arising from chronic myelomonocytic leukemia is currently classified as acute myeloid leukemia with myelodysplasia-related changes, a high-risk subtype. However, the specific features of these cases have not been well described. We studied 38 patients with chronic myelomonocytic leukemia who progressed to acute myeloid leukemia. We compared the clinicopathologic and genetic features of these cases with 180 patients with de novo acute myeloid leukemia and 34 patients with acute myeloid leukemia following myelodysplastic syndromes. We also examined features associated with progression from chronic myelomonocytic leukemia to acute myeloid leukemia by comparing the progressed chronic myelomonocytic leukemia cases with a cohort of chronic myelomonocytic leukemia cases that did not transform to acute myeloid leukemia. Higher white blood cell count, marrow cellularity, karyotype risk score, and Revised International Prognostic Scoring System score were associated with more rapid progression from chronic myelomonocytic leukemia to acute myeloid leukemia. Patients with acute myeloid leukemia ex chronic myelomonocytic leukemia were older (P<0.01) and less likely to receive aggressive treatment (P=0.02) than de novo acute myeloid leukemia patients. Most cases showed monocytic differentiation and fell into the intermediate acute myeloid leukemia karyotype risk group; 55% had normal karyotype and 17% had NPM1 mutation. Median overall survival was 6 months, which was inferior to de novo acute myeloid leukemia (17 months, P=0.002) but similar to post myelodysplastic syndrome acute myeloid leukemia. On multivariate analysis of all acute myeloid leukemia patients, only age and karyotype were independent prognostic variables for overall survival. Our findings indicate that acute myeloid leukemia following chronic myelomonocytic leukemia displays aggressive behavior and support placement of these cases within the category of acute myeloid leukemia with myelodysplasia-related changes. The poor prognosis of these patients may be related to an older population and lack of favorable-prognosis karyotypes that characterize many de novo acute myeloid leukemia cases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23307061     DOI: 10.1038/modpathol.2012.218

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  12 in total

1.  Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

Authors:  X Cahu; P Chevallier; A Clavert; F Suarez; M Michallet; L Vincent; S Vigouroux; D Blaise; C Mariette; K Bilger; M Robin; I Yakoub-Agha; R Peffault de Latour; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

2.  NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

Authors:  Guillermo Montalban-Bravo; Rashmi Kanagal-Shamanna; Koji Sasaki; Keyur Patel; Irene Ganan-Gomez; Elias Jabbour; Tapan Kadia; Farhad Ravandi; Courtney DiNardo; Gautham Borthakur; Koichi Takahashi; Marina Konopleva; Rami S Komrokji; Amy DeZern; Teodora Kuzmanovic; Jaroslaw Maciejewski; Sherry Pierce; Simona Colla; Mikkael A Sekeres; Hagop Kantarjian; Carlos Bueso-Ramos; Guillermo Garcia-Manero
Journal:  Blood Adv       Date:  2019-03-26

3.  Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.

Authors:  Konnie Hebeda; Ludmila Boudova; Christine Beham-Schmid; Attilio Orazi; Hans-Michael Kvasnicka; Umberto Gianelli; Alexandar Tzankov
Journal:  Ann Hematol       Date:  2020-10-31       Impact factor: 3.673

4.  Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy.

Authors:  Pasquale Niscola; Andrea Tendas; Laura Scaramucci; Marco Giovannini; Daniela Piccioni; Paolo de Fabritiis
Journal:  Blood Res       Date:  2014-03-24

5.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

Review 6.  Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.

Authors:  Anna Bochicchio; Sandra Jordaan; Valeria Losasso; Shivan Chetty; Rodrigo Casasnovas Perera; Emiliano Ippoliti; Stefan Barth; Paolo Carloni
Journal:  Biomedicines       Date:  2017-02-17

7.  Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report.

Authors:  Huan Liu; Juan Cheng; Long Zhao; Qian Xu; Mingming Xue; Shuling Zhang; Bei Liu
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

Review 8.  NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?

Authors:  Fabio Forghieri; Vincenzo Nasillo; Ambra Paolini; Francesca Bettelli; Valeria Pioli; Davide Giusti; Andrea Gilioli; Corrado Colasante; Gloria Acquaviva; Giovanni Riva; Patrizia Barozzi; Rossana Maffei; Leonardo Potenza; Roberto Marasca; Claudio Fozza; Enrico Tagliafico; Tommaso Trenti; Patrizia Comoli; Giuseppe Longo; Mario Luppi
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

9.  Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.

Authors:  Antònia Banús-Mulet; Amaia Etxabe; Josep Maria Cornet-Masana; Miguel Ángel Torrente; María Carmen Lara-Castillo; Laura Palomo; Meritxell Nomdedeu; Marina Díaz-Beyá; Francesc Solé; Benet Nomdedeu; Jordi Esteve; Ruth M Risueño
Journal:  Sci Rep       Date:  2018-09-17       Impact factor: 4.379

10.  Acute Myeloid Leukemia with Co-mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia.

Authors:  Steven M Johnson; Daniel R Richardson; Jonathan Galeotti; Sonia Esparza; Anqi Zhu; Yuri Fedoriw; Karen E Weck; Matthew C Foster; Catherine C Coombs; Joshua F Zeidner; Nathan D Montgomery
Journal:  Hemasphere       Date:  2019-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.